Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accounts Payables (2016 - 2026)

Ani Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $62.6 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 37.08% to $62.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.6 million, a 37.08% increase, with the full-year FY2025 number at $62.6 million, up 37.08% from a year prior.
  • Accounts Payables hit $62.6 million in Q4 2025 for Ani Pharmaceuticals, down from $69.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for ANIP hit a ceiling of $69.8 million in Q3 2025 and a floor of $11.5 million in Q3 2021.
  • Historically, Accounts Payables has averaged $36.8 million across 5 years, with a median of $33.4 million in 2023.
  • Biggest five-year swings in Accounts Payables: dropped 14.47% in 2021 and later soared 113.0% in 2022.
  • Tracing ANIP's Accounts Payables over 5 years: stood at $23.0 million in 2021, then increased by 27.6% to $29.3 million in 2022, then grew by 25.18% to $36.7 million in 2023, then increased by 24.46% to $45.7 million in 2024, then surged by 37.08% to $62.6 million in 2025.
  • Business Quant data shows Accounts Payables for ANIP at $62.6 million in Q4 2025, $69.8 million in Q3 2025, and $54.6 million in Q2 2025.